Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7019
-0.0128 (-1.79%)
Aug 14, 2025, 1:50 PM - Market open
Xilio Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Buy
Price Target
$3.00
Upside
+327.41%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $2 | Buy | Initiates | $2 | +184.94% | Aug 6, 2025 |
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +469.88% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +897.29% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +897.29% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +1,324.70% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +897.29% | Dec 21, 2022 |
| Raymond James | Raymond James | Buy Maintains $31 → $13 | Buy | Maintains | $31 → $13 | +1,752.12% | Nov 10, 2022 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $32 → $20 | Buy | Maintains | $32 → $20 | +2,749.41% | Aug 10, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +5,028.94% | Jan 10, 2022 |
| Raymond James | Raymond James | Buy Initiates $31 | Buy | Initiates | $31 | +4,316.58% | Nov 16, 2021 |
| Cowen & Co. | Cowen & Co. | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 16, 2021 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $32 | Buy | Initiates | $32 | +4,459.05% | Nov 16, 2021 |